# US 2004/0082533 A1 · Electro-gene therapy of arthritis by using an expression plasmid encoding the soluble p75 tumor necrosis factor receptor-Fc fusion protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082533 A1
- Document ID: US20040082533A1
- Status: Published application
- Kind: A1
- Application number: 10/637,864
- Filed: 2003-08-08
- Published: 2004-04-29
- Earliest claimed: 2002-08-09
- Inventors: Jong-Mook Kim; Seong-Hyun Ho; Woong Hahn; Seung-Shin Yu; Sunyoung Kim
- Web page: https://patentgrep.com/patent/US20040082533A1

## CPC

- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61N 1/325: {for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body (electrodes for external use A61N1/0428)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The electroporation-mediated delivery of plasmid containing cDNA for soluble p75 TNF (tumor necrosis factor) receptor linked to the Fc portion of human IgG1 (sTNFR:Fc) can be effectively used for the treatment of arthritis in a mammal.

## Claims

### Claim 1

A pharmaceutical composition for electro-gene therapy of arthritis in a mammal, which comprises a therapeutically effective amount of a DNA encoding soluble p75 TNF (tumor necrosis factor) receptor linked to the Fc portion of human IgG1 (sTNFR:Fc) and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DNA encoding sTNFR:Fc is contained in an expression vector.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the expression vector is pCK-sTNFR:Fc.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the mammal is human.

### Claim 5 (depends on 1)

The composition of claim 1, which is administered with in vivo electroporation.

### Claim 6 (depends on 1)

The composition of claim 1, which is administered to the muscles.

### Claim 7

A method for electro-gene therapy of arthritis in a mammal, which comprises administering a therapeutically effective amount of a DNA encoding sTNFR:Fc via in vivo electroporation.

### Claim 8 (depends on 7)

The method of claim 7, wherein the DNA encoding sTNFR:Fc is contained in an expression vector.

### Claim 9 (depends on 8)

The method of claim 8, wherein the expression vector is pCK-sTNFR:Fc.

### Claim 10 (depends on 7)

The method of claim 7, wherein the mammal is human.

### Claim 11 (depends on 7)

The method of claim 7, wherein the DNA encoding sTNFR:Fc is administered to the muscles.

### Claim 12 (depends on 7)

The method of claim 7, wherein the therapeutically effective amount of the DNA encoding sTNFR:Fc ranges from 0.005 to 50 mg/kg body weight.
